Article
Multidisciplinary Sciences
Thang Quyet Nguyen, Seri Koh, Jiin Kwon, Soyeon Jang, Wonchull Kang, Jin Kuk Yang
Summary: p97 is a human AAA+ ATPase involved in various cellular processes. METTL21D is a Lys-specific methyltransferase that methylates Lys315 of p97, known as VCPKMT. The structures of S-adenosyl-L-methionine-bound VCPKMT and S-adenosyl-L-homocysteine-bound VCPKMT complexed with p97 N/D1 were reported, revealing the molecular details of p97 recognition and methylation by VCPKMT. The study also investigated the enhancement of p97 methylation through cooperation between VCPKMT and ASPL C-terminus.
Article
Oncology
Jieqiong Wang, Yajie Chen, Canhua Huang, Qian Hao, Shelya X. Zeng, Sara Omari, Yu Zhang, Xiang Zhou, Hua Lu
Summary: Valosin-containing protein (VCP) has been identified as a novel regulator of p53-R273H stability, stabilizing p53-R273H through binding to MDM2 and disrupting its association with mutant p53, while inhibition of VCP leads to ubiquitination and degradation of p53-R273H, promoting cell death. VCP may serve as a potential target for the development of pancreatic cancer therapy.
Review
Medicine, Research & Experimental
Jiahui Fu, Jin Zhang, Xiya Chen, Zhiying Liu, Xuetao Yang, Zhendan He, Yue Hao, Bo Liu, Dahong Yao
Summary: ATPase family AAA domain-containing protein 2 (ATAD2) is a new oncogene closely associated with epigenetic modifications in human cancers. It functions as a coactivator of transcription factors and regulates the expression of downstream oncogenes or tumor suppressors. The dominant structure of ATAD2 makes it a potential therapeutic target in cancer, and small-molecule inhibitors have been discovered. This review focuses on summarizing the structural features and biological functions of ATAD2 as well as the existing small-molecule inhibitors targeting ATAD2 for potential cancer therapy.
Article
Medicine, General & Internal
Jue Wang, Zongrui Jin, Guolin Wu, Zhenfeng Deng, Jilong Wang, Banghao Xu, Hai Zhu, Ya Guo, Zhang Wen
Summary: Hypoxia-related gene signature can serve as a potential prognostic marker for hepatocellular carcinoma (HCC) and is associated with tumor immune infiltration.
Article
Medicine, Research & Experimental
Mingxing Xu, Jianliang Xu, Dun Zhu, Rishun Su, Baoding Zhuang, Ruiyun Xu, Lingli Li, Shuxian Chen, Yunbiao Ling
Summary: The disordered expression of some PRDX family members is associated with the prognosis of HCC patients, suggesting that these PRDX family members may become new molecular targets for the treatment and prognosis prediction of HCC.
JOURNAL OF TRANSLATIONAL MEDICINE
(2021)
Article
Oncology
Nobuhiko Nakagawa, Fuminori Sonohara, Katsuhito Tanaka, Yuki Sunagawa, Yoshikuni Inokawa, Hideki Takami, Masamichi Hayashi, Suguru Yamada, Mitsuro Kanda, Chie Tanaka, Goro Nakayama, Masahiko Koike, Yasuhiro Kodera
Summary: This study revealed that high YTHDF2 expression in HCC tissues was associated with cancer recurrence.
Article
Oncology
Yang Zhou, Dengliang Lei, Gangli Hu, Fang Luo
Summary: We aimed to propose a cell cycle-related multi/mRNA signature (CCS) for prognosis prediction and uncover new tumor-driver genes for hepatocellular carcinoma (HCC). The CCS was constructed using statistical analysis and Cox regression analyses. Predictive capacity and clinical practicality of the signature were evaluated and validated. TICRR was identified as a tumor-driver gene for HCC through functional experiments.
FRONTIERS IN ONCOLOGY
(2022)
Article
Genetics & Heredity
Chenxi Pan, Nan Luo, Kun Guo, Wenbo Wang, Lei Li, Ning Fan, Yu Tian
Summary: The high expression of CBX1, CBX2, CBX3, CBX6, and CBX8 was associated with poor survival rates in hepatocellular carcinoma patients. CBX2 and CBX3 were significantly correlated with poor prognosis for hepatocellular carcinoma patients. CBX3 was strongly correlated with immune cell infiltration and involved in regulation of methylation of Histone H3-K27.
FRONTIERS IN GENETICS
(2022)
Article
Cell Biology
Xinghua Huang, Huaxiang Wang, Fengfeng Xu, Lizhi Lv, Ruling Wang, Bin Jiang, Tingting Liu, Huanzhang Hu, Yi Jiang
Summary: The expression level of CCT7 is higher in hepatocellular carcinoma (HCC) tissues compared to normal tissues, and this high expression is associated with poor prognosis. CCT7 expression remains higher in HCC tissues compared to normal tissues in early-stage disease and low alpha-fetoprotein expression patients, and it has better diagnostic value than alpha-fetoprotein. Higher CCT7 expression is also associated with poorer overall and recurrence-free survival in HCC patients.
Article
Oncology
Weiyu Dai, Jing Wang, Zhi Wang, Yizhi Xiao, Jiaying Li, Linjie Hong, Miaomiao Pei, Jieming Zhang, Ping Yang, Xiaosheng Wu, Weimei Tang, Xiaoling Jiang, Ping Jiang, Li Xiang, Aimin Li, Jianjiao Lin, Side Liu, Jide Wang
Summary: The study identified the potential application values of the TRIM family for outcome prediction in HCC. A novel TRIM family gene-based signature was built for predicting overall survival in HCC, showing good performance in prediction. High expressions of certain TRIM family members were significantly associated with poor overall survival in HCC patients.
FRONTIERS IN ONCOLOGY
(2021)
Article
Cell Biology
Sicheng Liu, Yaguang Zhang, Lei Qiu, Su Zhang, Yang Meng, Canhua Huang, Zhixin Chen, Bo Zhang, Junhong Han
Summary: This study demonstrates the association between ac4C-related mRNA modification patterns and the prognosis of hepatocellular carcinoma patients. The ac4Cscore is identified as a novel marker for predicting patients' prognosis and response to immunotherapy.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Susan Costantini, Francesca Capone, Andrea Polo, Palmina Bagnara, Alfredo Budillon
Summary: The review outlines the role of VCP/p97 in different cancers and its potential as a cancer biomarker and therapeutic target, while also addressing the challenges posed by VCP mutations in resistance to inhibitors.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Pharmacology & Pharmacy
Xu-Xiao Chen, Bao-Hua Zhang, Yan-Cen Lu, Zi-Qiang Li, Cong-Yan Chen, Yu-Chen Yang, Yong-Jun Chen, Di Ma
Summary: This study established a robust 16-gene AS signature for predicting tumor relapse in stage I-III HCC, which is significantly associated with the immune status of the HCC microenvironment.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Genetics & Heredity
Shanshan Chen, Yongchao Zhang, Xiaoyan Ding, Wei Li
Summary: Through bioinformatic analysis, a total of 327 upregulated and 422 downregulated overlapping DEGs between HCC and noncancerous liver tissues were identified. A ceRNA network was successfully constructed, including five lncRNAs, six circRNAs, eight miRNAs, and five mRNAs, with the ZFAS1/hsa-miR-150-5p/GINS1 ceRNA regulatory axis showing high diagnostic and prognostic value.
FRONTIERS IN GENETICS
(2022)
Article
Biochemistry & Molecular Biology
Shenglan Huang, Cairong Dong, Jian Zhang, Shumin Fu, Yaqin Lv, Jianbing Wu
Summary: EFNA3, EFNA4, and EFNB1 are identified as independent prognostic factors for HCC patients and are closely correlated with tumor immunity, suggesting they may serve as novel therapeutic targets and biomarkers for immunotherapy.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2022)